The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The submission is based on data from the phase 3 SENTRY trial, which evaluated the combination in JAK inhibitor-naive patients and demonstrated spleen volume reduction and an overall survival signal.
Feedback from the FDA supports advancing the therapy into STRIDE-MDS, a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating the efficacy, safety, and dose selection of LYT-200.
Registration for the 4th SOHO-Israel Meeting & 10th International Davidoff Conference is open for online and in-person registration. The meeting is scheduled for November 19–20, 2026.
Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, discusses initial results from the phase 2 RESTORE-PV trial evaluating DISC-3405 in patients with polycythemia vera (PV).
The Board of Directors and the Steering Committee of the Society of Hematologic Oncology (SOHO) are pleased to announce that Valeria Santini, MD, has assumed the position of SOHO president in September 2026. She will oversee the society during the 2026-2027 term and will chair the Fifteenth Annual Meeting of SOHO in Houston, Texas.
The study, led by Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center in Houston, was presented at the Fourteenth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
